To address the first question, we correlated the microarray-based mRNA expression of the 5 CSA targets (EIF2AK3, MAPK12/p38γ, PAK1, RPS6KA3, and WNK3) in a panel of 60 tumor lines of the NCI, USA, with 83 standard anticancer agents. The gene discussed is EIF2AK3; the disease is neoplasm.